Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Wall Street opens higher ahead of Yellen speech
- Apollo Global to Acquire Rackspace (RAX) in $4.3B Deal
- Icahn Shopped Herbalife (HLF) Stake to Ackman Group
- U.S. second-quarter growth trimmed to 1.1 percent; consumer spending raised
- Pre-Open Stock Movers 08/26: (PQ) (PSTG) (NVAX) Higher; (ESI) (TLND) (HLF) Lower (more...)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Mettler-Toledo Intl. (MTD) to replace Johnson Controls (JCI) in S&P 500
- Valeant (VRX) Derm NRx Up Week-Over-Week, Ophth NRx Down - RBC
- Sarepta Therapeutics (SRPT) Gains Ahead of FDA Decision
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!